<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25968" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ghlichloo</surname>
            <given-names>Ida</given-names>
          </name>
          <aff>California Northstate University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gerriets</surname>
            <given-names>Valerie</given-names>
          </name>
          <aff>California Northstate University College of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ida Ghlichloo declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Valerie Gerriets declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25968.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">NSAIDs are a class of medications used to treat pain, fever, and other inflammatory processes. This activity describes the indications, mechanism of action, administration, adverse effects, contraindications, monitoring, and important points for providers regarding NSAIDs.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of NSAIDs.</p></list-item><list-item><p>Describe the potential adverse effects of NSAIDs.</p></list-item><list-item><p>Review the potential toxicity of NSAIDs.</p></list-item><list-item><p>Summarize interprofessional team strategies for improving care and outcomes when using NSAID therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25968&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25968">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25968.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Nonsteroidal&#x000a0;anti-inflammatory drugs (NSAIDs)&#x000a0;are a drug class FDA-approved for use as antipyretic, anti-inflammatory, and analgesic agents.<xref ref-type="bibr" rid="article-25968.r1">[1]</xref>&#x000a0;These effects make NSAIDs useful for treating muscle pain, dysmenorrhea, arthritic conditions, pyrexia, gout, migraines, and used as opioid-sparing agents in certain acute trauma cases.<xref ref-type="bibr" rid="article-25968.r2">[2]</xref><xref ref-type="bibr" rid="article-25968.r3">[3]</xref><xref ref-type="bibr" rid="article-25968.r4">[4]</xref></p>
        <p>NSAIDs are typically divided into groups based on their chemical structure and selectivity: acetylated salicylates (aspirin), non-acetylated salicylates (diflunisal, salsalate), propionic acids (naproxen, ibuprofen, acetic acids (diclofenac, indomethacin), enolic acids (meloxicam, piroxicam) anthranilic acids (meclofenamate, mefenamic acid), naphthylalanine (nabumetone), and selective COX-2 inhibitors (celecoxib, etoricoxib).&#x000a0;&#x000a0;&#x000a0;</p>
        <p>Topical NSAIDs (diclofenac gel) are also available for use in acute tenosynovitis, ankle sprains, and soft tissue injuries.<xref ref-type="bibr" rid="article-25968.r5">[5]</xref><xref ref-type="bibr" rid="article-25968.r6">[6]</xref><xref ref-type="bibr" rid="article-25968.r7">[7]</xref><xref ref-type="bibr" rid="article-25968.r8">[8]</xref></p>
        <p>Listed below are the FDA-approved NSAIDs (organized alphabetically):</p>
        <p>
<bold>Non-selective NSAIDs</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Diclofenac</p>
          </list-item>
          <list-item>
            <p>Diflunisal</p>
          </list-item>
          <list-item>
            <p>Etodolac</p>
          </list-item>
          <list-item>
            <p>Fenoprofen</p>
          </list-item>
          <list-item>
            <p>Flurbiprofen</p>
          </list-item>
          <list-item>
            <p>Ibuprofen</p>
          </list-item>
          <list-item>
            <p>Indomethacin</p>
          </list-item>
          <list-item>
            <p>Ketoprofen</p>
          </list-item>
          <list-item>
            <p>Ketorolac</p>
          </list-item>
          <list-item>
            <p>Mefenamic acid</p>
          </list-item>
          <list-item>
            <p>Meloxicam</p>
          </list-item>
          <list-item>
            <p>Nabumetone</p>
          </list-item>
          <list-item>
            <p>Naproxen</p>
          </list-item>
          <list-item>
            <p>Oxaprozin</p>
          </list-item>
          <list-item>
            <p>Piroxicam</p>
          </list-item>
          <list-item>
            <p>Sulindac</p>
          </list-item>
          <list-item>
            <p>Tolmetin</p>
          </list-item>
        </list>
        <p>
<bold>COX-2 Selective NSAIDs</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Celecoxib</p>
          </list-item>
          <list-item>
            <p>Rofecoxib</p>
          </list-item>
          <list-item>
            <p>Valdecoxib</p>
          </list-item>
        </list>
        <p>(However, rofecoxib and valdecoxib were withdrawn&#x000a0;from the market&#x000a0;in 2004&#x000a0;and 2005, respectively)</p>
      </sec>
      <sec id="article-25968.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The main mechanism of action of NSAIDs is the inhibition of the enzyme cyclooxygenase (COX). Cyclooxygenase is required to convert arachidonic acid into thromboxanes, prostaglandins, and prostacyclins.<xref ref-type="bibr" rid="article-25968.r9">[9]</xref> The therapeutic effects of NSAIDs are attributed to the lack of these eicosanoids. Specifically, thromboxanes play a role in platelet adhesion, prostaglandins cause vasodilation, increase the temperature set-point in the hypothalamus, and play a role in anti-nociception.&#x000a0;</p>
        <p>There are two cyclooxygenase isoenzymes, COX-1 and COX-2. COX-1 gets constitutively expressed in the body, and it plays a role in maintaining gastrointestinal mucosa lining, kidney function, and platelet aggregation. COX-2 is not constitutively expressed in the body; and instead, it inducibly expresses during an inflammatory response. Most of the NSAIDs are nonselective and inhibit both COX-1 and COX-2. However, COX-2 selective NSAIDs (ex. celecoxib) only target COX-2 and therefore have a different side effect profile. Importantly, because COX-1 is the prime mediator for ensuring gastric mucosal integrity and COX-2 is mainly involved in inflammation, COX-2 selective NSAIDs should provide anti-inflammatory relief without compromising the gastric mucosa.<xref ref-type="bibr" rid="article-25968.r10">[10]</xref></p>
      </sec>
      <sec id="article-25968.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Most commonly, NSAIDs are available as oral tablets. According to the package insert, the dosage for the most common over-the-counter NSAIDs are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Ibuprofen: for 200 mg tablets, 1 to 2 tablets every 4 to 6 hours while symptoms persist. The daily limit for ibuprofen is 1200 mg.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Aspirin regular strength: for 325 mg tablets, 1 to 2 tablets every 4 hours, or 3 tablets every 6 hours. The daily limit for aspirin is 4000 mg.</p>
          </list-item>
          <list-item>
            <p>Naproxen sodium: for 220 mg tablets, 1 to 2 tablets every 8 to 12 hours. The daily limit for naproxen sodium is 660 mg.&#x000a0;</p>
          </list-item>
        </list>
        <p>Topical NSAIDs are also available (diclofenac sodium 1.5% topical solution, diclofenac hydroxyethyl pyrrolidine 1.3% patch, and diclofenac sodium gel 1%). They are most useful for treating pain due to soft-tissue injuries and osteoarthritis.<xref ref-type="bibr" rid="article-25968.r8">[8]</xref></p>
        <p>Specific NSAIDs can also be administered parenterally; for example, intravenous ibuprofen is available, given as a 30-minute infusion; this can be used as a non-opioid analgesic to manage pain and can also reduce fever. Trials have shown that using intravenous ibuprofen and morphine in postoperative adult patients can lower the total use of morphine. For treating pyrexia, an initial 400mg dose then 400 or 100 to 200 mg every 4 to 6 hours as needed. For the treatment of pain, 400 to 800 mg, every 6 hours as needed, is the recommended dose regimen.<xref ref-type="bibr" rid="article-25968.r11">[11]</xref>&#x000a0;Ketorolac is also available for parenteral administration.&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-25968.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>NSAIDs have well-known adverse effects affecting the gastric mucosa, renal system, cardiovascular system, hepatic system, and hematologic system.</p>
        <p><bold>Gastric adverse effects </bold>are likely due to the inhibition of COX-1, preventing the creation of prostaglandins that protect the gastric mucosa. The damage is more likely in a patient that has a prior history of peptic ulcers. Since it is COX-1 specific, the use of COX-2 selective NSAIDs is a lower-risk alternative.<xref ref-type="bibr" rid="article-25968.r12">[12]</xref></p>
        <p><bold>Renal adverse effects</bold>&#x000a0;are because COX-1 and COX-2 facilitate the production of prostaglandins that play a role in renal hemodynamics. In a patient with normal renal function, inhibition of prostaglandin synthesis does not pose a large problem; however, in a patient with renal dysfunction, these prostaglandins play a greater role and can be the source of problems when reduced via NSAIDs. Complications that can occur&#x000a0;include acute renal dysfunction, fluid and electrolyte disorders, renal papillary necrosis, and nephrotic syndrome/ interstitial nephritis.<xref ref-type="bibr" rid="article-25968.r13">[13]</xref></p>
        <p><bold>Cardiovascular adverse effects</bold>&#x000a0;can also be increased with NSAID use; these include MI, thromboembolic events, and atrial fibrillation. Diclofenac seems to be the NSAID with the highest reported increase in adverse cardiovascular events.<xref ref-type="bibr" rid="article-25968.r14">[14]</xref></p>
        <p><bold>Hepatic adverse effects&#x000a0;</bold>are less common; NSAID-associated risk of hepatotoxicity (raised aminotransferase levels) is not very common, and liver-related hospitalization is very rare. Among the various NSAIDs, Diclofenac has a higher rate of hepatotoxic effects.<xref ref-type="bibr" rid="article-25968.r15">[15]</xref>&#x000a0;</p>
        <p><bold>Hematologic adverse effects&#x000a0;</bold>are possible, particularly with&#x000a0;nonselective NSAIDs&#x000a0;due to their antiplatelet activity. This antiplatelet effect typically only poses a problem&#x000a0;if the patient has a history of GI ulcers, diseases that impair platelet activity (hemophilia, thrombocytopenia, von Willebrand, etc.), and in some perioperative cases.<xref ref-type="bibr" rid="article-25968.r16">[16]</xref></p>
        <p><bold>Other minor&#x000a0;adverse effects</bold> include anaphylactoid reactions that involve the skin and pulmonary systems, like urticaria and aspirin-exacerbated respiratory disease.<xref ref-type="bibr" rid="article-25968.r17">[17]</xref><xref ref-type="bibr" rid="article-25968.r18">[18]</xref></p>
        <p>For a complete list of adverse effects for an individual NSAID, please see the StatPearls article for that particular drug.&#x000a0;</p>
      </sec>
      <sec id="article-25968.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>According to the package insert, NSAIDs are contraindicated in patients:</p>
        <list list-type="bullet">
          <list-item>
            <p>With NSAID hypersensitivity or salicylate hypersensitivity, as well as in patients who have experienced an allergic reaction (urticaria, asthma, etc.) after taking NSAIDs&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Who have undergone coronary artery bypass graft surgery</p>
          </list-item>
          <list-item>
            <p>During the third trimester of pregnancy</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25968.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Recommended monitoring includes a CBC, renal tests, and hepatic panel. These recommendations are from the American College of Rheumatology for use in rheumatoid arthritis patients who use NSAIDs chronically and who have no comorbidities nor history of complications. Monitoring is less common in patients not considered high risk for NSAID toxicity. However, NSAIDs are&#x000a0;either contraindicated, or their use requires monitoring in patients with liver or renal problems.<xref ref-type="bibr" rid="article-25968.r19">[19]</xref></p>
      </sec>
      <sec id="article-25968.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>NSAID toxicity can manifest as GI bleeding, hypertension, hepatotoxicity, and renal damage.&#x000a0;<xref ref-type="bibr" rid="article-25968.r19">[19]</xref>&#x000a0;Typically,&#x000a0;acute NSAID overdose is asymptomatic or has negligible gastrointestinal symptoms. However, other symptoms of toxicity complications may include anion gap metabolic acidosis, coma, convulsions, and acute renal failure. Also, NSAIDs can confer gastrointestinal damage by inhibiting COX-1, which causes decrease gastric mucosa production. Nephrotoxicity&#x000a0;can also occur&#x000a0;with NSAID use because these medications reduce prostaglandin levels, which are&#x000a0;essential for the vasodilation of the renal arterioles.&#x000a0; Lastly, neurologic toxicity can present with drowsiness, confusion, nystagmus, blurred vision, diplopia, headache, and tinnitus.<xref ref-type="bibr" rid="article-25968.r20">[20]</xref></p>
      </sec>
      <sec id="article-25968.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The general public widely uses NSAIDs because of their wide range of commonly encountered indications. Patient education on the use of NSAIDs is an important piece of care that providers need to pay attention to because of the many possible adverse effects on multiple different organ systems. Because these adverse effects occur at a much higher rate in patients with specific comorbidities, it is crucial for physicians, nurses, and pharmacists to pay close attention to a patient's history and to educate the patient accordingly on risks and dosing. The treating clinician will initiate therapy, whether for a short or long-term regimen. The pharmacist will need to verify the dosing and administration and check for potential drug-drug interactions. Pharmacists should also offer patient counseling on how to best use their NSAID and minimize adverse events; this is particularly the case when the patient uses NSAIDs as an OTC agent. Nursing must also take a careful medication history and include OTC NSAID use, so the clinician can make an informed choice for prescribing NSAID therapy. MUrses, pharmacists, and clinicians all need to be cognizant of the signs and symptoms of NSAID toxicity or adverse effects to make changes to the patient's regimen as needed.</p>
        <p>The healthcare team should communicate and work together to ensure that each patient receives the proper dose for their specific condition and comorbidities, high enough for efficacy but as low as possible to reduce the incidence of adverse effects. Through collaborative interprofessional teamwork, NSAID therapy can confer maximum benefit with minimal downside. [Level 5]</p>
      </sec>
      <sec id="article-25968.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25968&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25968">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25968/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25968">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25968.s11">
        <title>References</title>
        <ref id="article-25968.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Phillips</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Currier</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>Analgesic pharmacology: II. Specific analgesics.</article-title>
            <source>J Am Acad Orthop Surg</source>
            <year>2004</year>
            <season>Jul-Aug</season>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>221</fpage>
            <page-range>221-33</page-range>
            <pub-id pub-id-type="pmid">15473674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25968.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dawood</surname>
                <given-names>MY</given-names>
              </name>
            </person-group>
            <article-title>Primary dysmenorrhea: advances in pathogenesis and management.</article-title>
            <source>Obstet Gynecol</source>
            <year>2006</year>
            <month>Aug</month>
            <volume>108</volume>
            <issue>2</issue>
            <fpage>428</fpage>
            <page-range>428-41</page-range>
            <pub-id pub-id-type="pmid">16880317</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25968.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shekelle</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Newberry</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>FitzGerald</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Motala</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>O'Hanlon</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Tariq</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Okunogbe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Shanman</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Management of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline.</article-title>
            <source>Ann Intern Med</source>
            <year>2017</year>
            <month>Jan</month>
            <day>03</day>
            <volume>166</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <page-range>37-51</page-range>
            <pub-id pub-id-type="pmid">27802478</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25968.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oyler</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Parli</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Bernard</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Procter</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Harned</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Nonopioid management of acute pain associated with trauma: Focus on pharmacologic options.</article-title>
            <source>J Trauma Acute Care Surg</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>79</volume>
            <issue>3</issue>
            <fpage>475</fpage>
            <page-range>475-83</page-range>
            <pub-id pub-id-type="pmid">26307883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25968.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zacher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Altman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bellamy</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Br&#x000fc;hlmann</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Da Silva</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Huskisson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Topical diclofenac and its role in pain and inflammation: an evidence-based review.</article-title>
            <source>Curr Med Res Opin</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>925</fpage>
            <page-range>925-50</page-range>
            <pub-id pub-id-type="pmid">18279583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25968.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van den Bekerom</surname>
                <given-names>MPJ</given-names>
              </name>
              <name>
                <surname>Sjer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Somford</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Bulstra</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Struijs</surname>
                <given-names>PAA</given-names>
              </name>
              <name>
                <surname>Kerkhoffs</surname>
                <given-names>GMMJ</given-names>
              </name>
            </person-group>
            <article-title>Non-steroidal anti-inflammatory drugs (NSAIDs) for treating acute ankle sprains in adults: benefits outweigh adverse events.</article-title>
            <source>Knee Surg Sports Traumatol Arthrosc</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>23</volume>
            <issue>8</issue>
            <fpage>2390</fpage>
            <page-range>2390-2399</page-range>
            <pub-id pub-id-type="pmid">24474583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25968.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>May</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Lovell</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hopkins</surname>
                <given-names>WG</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness of 1% diclofenac gel in the treatment of wrist extensor tenosynovitis in long distance kayakers.</article-title>
            <source>J Sci Med Sport</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>59</fpage>
            <page-range>59-65</page-range>
            <pub-id pub-id-type="pmid">16787761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25968.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barkin</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Topical Nonsteroidal Anti-Inflammatory Drugs: The Importance of Drug, Delivery, and Therapeutic Outcome.</article-title>
            <source>Am J Ther</source>
            <year>2015</year>
            <season>Sep-Oct</season>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>388</fpage>
            <page-range>388-407</page-range>
            <pub-id pub-id-type="pmid">22367354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25968.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vane</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs.</article-title>
            <source>Nat New Biol</source>
            <year>1971</year>
            <month>Jun</month>
            <day>23</day>
            <volume>231</volume>
            <issue>25</issue>
            <fpage>232</fpage>
            <page-range>232-5</page-range>
            <pub-id pub-id-type="pmid">5284360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25968.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chaiamnuay</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Allison</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2006</year>
            <month>Oct</month>
            <day>01</day>
            <volume>63</volume>
            <issue>19</issue>
            <fpage>1837</fpage>
            <page-range>1837-51</page-range>
            <pub-id pub-id-type="pmid">16990630</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25968.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scott</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Intravenous ibuprofen: in adults for pain and fever.</article-title>
            <source>Drugs</source>
            <year>2012</year>
            <month>May</month>
            <day>28</day>
            <volume>72</volume>
            <issue>8</issue>
            <fpage>1099</fpage>
            <page-range>1099-109</page-range>
            <pub-id pub-id-type="pmid">22621696</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25968.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sostres</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gargallo</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Arroyo</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Lanas</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract.</article-title>
            <source>Best Pract Res Clin Gastroenterol</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>121</fpage>
            <page-range>121-32</page-range>
            <pub-id pub-id-type="pmid">20227026</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25968.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whelton</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications.</article-title>
            <source>Am J Med</source>
            <year>1999</year>
            <month>May</month>
            <day>31</day>
            <volume>106</volume>
            <issue>5B</issue>
            <fpage>13S</fpage>
            <page-range>13S-24S</page-range>
            <pub-id pub-id-type="pmid">10390124</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25968.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harirforoosh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Asghar</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Jamali</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications.</article-title>
            <source>J Pharm Pharm Sci</source>
            <year>2013</year>
            <volume>16</volume>
            <issue>5</issue>
            <fpage>821</fpage>
            <page-range>821-47</page-range>
            <pub-id pub-id-type="pmid">24393558</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25968.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sriuttha</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sirichanchuen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Permsuwan</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials.</article-title>
            <source>Int J Hepatol</source>
            <year>2018</year>
            <volume>2018</volume>
            <fpage>5253623</fpage>
            <pub-id pub-id-type="pmid">29568654</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25968.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schafer</surname>
                <given-names>AI</given-names>
              </name>
            </person-group>
            <article-title>Effects of nonsteroidal anti-inflammatory therapy on platelets.</article-title>
            <source>Am J Med</source>
            <year>1999</year>
            <month>May</month>
            <day>31</day>
            <volume>106</volume>
            <issue>5B</issue>
            <fpage>25S</fpage>
            <page-range>25S-36S</page-range>
            <pub-id pub-id-type="pmid">10390125</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25968.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berkes</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Anaphylactic and anaphylactoid reactions to aspirin and other NSAIDs.</article-title>
            <source>Clin Rev Allergy Immunol</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>137</fpage>
            <page-range>137-48</page-range>
            <pub-id pub-id-type="pmid">12668894</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25968.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Szczeklik</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Adverse reactions to aspirin and nonsteroidal anti-inflammatory drugs.</article-title>
            <source>Ann Allergy</source>
            <year>1987</year>
            <month>Nov</month>
            <volume>59</volume>
            <issue>5 Pt 2</issue>
            <fpage>113</fpage>
            <page-range>113-8</page-range>
            <pub-id pub-id-type="pmid">3318575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25968.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rothenberg</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Holcomb</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Guidelines for Monitoring of NSAIDS: Who Listened?</article-title>
            <source>J Clin Rheumatol</source>
            <year>2000</year>
            <month>Oct</month>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>258</fpage>
            <page-range>258-65</page-range>
            <pub-id pub-id-type="pmid">19078482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25968.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hunter</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Dargan</surname>
                <given-names>PI</given-names>
              </name>
            </person-group>
            <article-title>The patterns of toxicity and management of acute nonsteroidal anti-inflammatory drug (NSAID) overdose.</article-title>
            <source>Open Access Emerg Med</source>
            <year>2011</year>
            <volume>3</volume>
            <fpage>39</fpage>
            <page-range>39-48</page-range>
            <pub-id pub-id-type="pmid">27147851</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
